Phase 1 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 1 to 21 years old
- People who have a solid tumour that tests positive for a protein called GPC3, confirmed by a laboratory test showing a strong enough level of that protein in the tumour cells
- People whose general health and ability to carry out daily activities meets a minimum score on a standard medical scale (called the Lansky or Karnofsky scale), indicating they are reasonably functional
- People with a life expectancy of at least 16 weeks
- People whose disease has come back or has not responded to standard treatments, and where a cure is no longer considered achievable with current therapies
- People who have recovered from the side effects of any previous cancer treatments before entering the trial
- People with liver cancer (hepatocellular carcinoma specifically) whose disease falls within a certain stage range (Barcelona Clinic Liver Cancer Stage A, B, or C) and whose liver function meets a specific scoring threshold (confirm with trial site)
- People whose kidneys, liver, blood counts, and oxygen levels meet minimum required levels as measured by blood and other tests
- People who are sexually active and are willing to use effective contraception for 6 months after receiving the treatment
- People (or their parent or guardian) who have been given a full explanation of the trial, understand it, and have signed a consent form
Who may not be able to join:
- People who have previously had an allergic reaction to products containing mouse proteins, or who have developed antibodies against mouse proteins (relevant only if prior mouse-based antibody treatments were received)
- People who have had an organ transplant
- People who are known to be HIV positive
- People who have an active bacterial, fungal, or viral infection (certain Hepatitis B and Hepatitis C cases may still be considered if specific treatment conditions are met — confirm with trial site)
- People who are pregnant or breastfeeding
- People with an uncontrolled infection at the time of treatment
- People who are currently taking systemic steroid medications at or above a certain dose, unless those medications are reduced or stopped at least 24 hours before the treatment infusion
- People with certain serious heart conditions, including severe heart failure, unstable chest pain, serious irregular heartbeat, a heart attack within the past 6 months, or a history of heart muscle inflammation
- People with an active autoimmune or inflammatory condition
- People who have received a live vaccine within 30 days before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David Steffin, MD, Baylor College of Medicine
Phone: (832) 824-4233
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Patients with Dose Limiting Toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.